Pathophysiologic mechanisms of itch in bullous pemphigoid - 19/06/20
, Christina Dorothy Kursewicz, BS a, Rachel Alison Fayne, BA a, Sonali Nanda, MS a, Serena Maya Shah a, Leigh Nattkemper, PhD a, Hiroo Yokozeki, MD, PhD b, Gil Yosipovitch, MD aAbstract |
Background |
One of the hallmarks of bullous pemphigoid (BP) is moderate to severe chronic itch. Managing this is difficult because little is known about the mechanisms of itch in BP.
Objective |
We sought to elucidate the pathophysiologic mechanisms of itch in BP.
Methods |
The expression of itch mediators in lesions of 24 patients with BP and 6 healthy individuals were examined through immunofluorescence staining. Furthermore, the expression of itch mediators and itch severity was correlated.
Results |
Itch severity was correlated with eosinophils, substance P, neurokinin 1R, interleukin (IL) 31 receptor A, oncostatin M receptor-β, IL-13, periostin, and basophils. There was also a trend between itch severity and IL-31 expression. Most of the cells expressing IL-31 or neurokinin 1R were identified as eosinophils. Intraepidermal nerve fiber density was decreased. Other itch mediators, including mast cells, IL-4, thymic stromal lymphopoietin, transient receptor potential vanilloid 1 and ankyrin 1, and protease activated receptor 2 were not significantly correlated with itch severity.
Limitations |
The relatively small sample size, the examination of protein expression exclusively through immunofluorescent analysis, and lack of functional assays in patients are the limitations.
Conclusions |
Multiple factors are involved in BP-associated itch, including eosinophils, substance P, neurokinin 1R, IL-31, IL-31 receptor A, oncostatin M receptor-β, IL-13, periostin, and basophils. They could be useful therapeutic targets.
Le texte complet de cet article est disponible en PDF.Key words : basophils, bullous pemphigoid, eosinophils, IL-13, IL-31, itch, NK1R, periostin, pruritus, substance P
Abbreviations used : AD, BP, IENFD, IL, IL-4Rα, NK1R, NRS, OSMRβ, PAR-2, SP, Th2, TSLP, TRPA1, TRPV1
Plan
| Funding sources: This work was partially supported by Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Young Scientists (B) (#17K16328) and an unrestricted fellowship grant from Menlo Therapeutics. |
|
| Conflicts of interest: Dr Yosipovitch is a scientific board member of Menlo, Trevi, Sienna, Sanofi, Regeneron, Galderma, Pfizer, Novartis, Bayer, Kiniksa, Eli Lilly, and Ortho, and has received research support from Pfizer, Sun Pharma, Leo,Menlo, and Kiniksa. Authors Hashimoto, Kursewicz, Fayne, Nanda, Shah, and Nattkemper have no conflicts of interest. |
Vol 83 - N° 1
P. 53-62 - juillet 2020 Retour au numéro
Article précédent
- Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series
- Rana Abdat, Reid A. Waldman, Valeria de Bedout, Annette Czernik, Michael Mcleod, Brett King, Samantha Gordon, Razzaque Ahmed, Anna Nichols, Marti Rothe, David Rosmarin
- Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways
- Michelle S. Min, Jianni Wu, Helen He, Juan Luis Sanz-Cabanillas, Ester Del Duca, Ning Zhang, Yael Renert-Yuval, Ana B. Pavel, Mark Lebwohl, Emma Guttman-Yassky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?